894 resultados para Harvey
Resumo:
This article deals with the relationship between the reader formation and the teaching of strategies of reading. We based our discussion in reading and childhood literature researchers as: Arena (2007a, 2007b, 2008 and 2010), Bajard (2002), Chiappini (1997), Coelho (2000), Cosson (2007), Foucambert (1994), Harvey & Goudivs (2007), Perroti (1986), Smith (1999), Soares (1999), Solé (2009), Zilberman (2005), and others. We dialogue with some points from the historical-cultural perspective, having a strong focus on a humanitarian literary education in elementary schools.
Resumo:
The discussion about reading as a cultural practice is a requirement that points to the school relevance to take itself as a social space of meanings construction and the need to use methodologies that focus on the knowledge construction process and the individual development in considering the teaching dynamics that encourage the strategies discovery for individual and collective work, facilitating that human culture object appropriation . The focus is on the relationships in the classroom and school context mediated by language to written language acquisition, with emphasis on reading. This study intends to contribute for the refl ection on the pedagogical implications derived from the organization of a teaching context, intentionally aimed at the teaching organization of reading strategies in the written language acquisition process. The hypothesis is that the reading strategies contribute to the contexts organization with pedagogical coherent and to the competent reader formation during the education act. The studies are based on Brazilian educators Girotto; SOUZA, 2010) and on North American educators (HAMPTON & Resnick, 2008; OWOCKI, 2003; WEDWICH & Wutz, 2008; HARVEY AND GOUDVINS, 2007), with the action research methodology.
Resumo:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Resumo:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Resumo:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Resumo:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Resumo:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Resumo:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Resumo:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Resumo:
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Resumo:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Resumo:
Adalimumab is a fully-human antibody that inhibits TNF alpha, with a significant efficacy for long-term maintenance of remission. Studies with this agent in Latin American Crohn's disease patients are scarce. The objective of this study was to outline clinical remission rates after 12 months of adalimumab therapy for Crohn's disease patients. Retrospective, single-center, observational study of a Brazilian case series of Crohn's disease patients under adalimumab therapy. Variables analyzed: demographic data, Montreal classification, concomitant medication, remission rates after 1, 4, 6 and 12 months. Remission was defined as Harvey-Bradshaw Index ≤ 4, and non-responder-imputation and last-observation-carried-forward analysis were used. The influence of infliximab on remission rates was analyzed by Fischer and Chi-square tests (P<0.05). Fifty patients, with median age of 35 years at therapy initiation, were included. Remission rates after 12 months of therapy were 54% under non-responder-imputation and 88% under last-observation-carried-forward analysis. After 12 months, remission on patients with previous infliximab occurred in 69.23% as compared to 94.59% in infliximab-naïve patients (P = 0.033). Adalimumab was effective in maintaining clinical remission after 12 months of therapy, with an adequate safety profile, and was also more effective in infliximab naïve patients.